Research Reports

Key takeaways

The company established an at-the-market equity offering program to sell up to $75.0 million of its common stock through Jefferies LLC.

The company is not obligated to sell any shares under the agreement, which can be terminated by either party with ten trading days' notice.

Net proceeds from any share sales are intended to fund clinical development of pelareorep, associated R&D expenses, operating costs, working capital, and general corporate purposes.

Jefferies will receive a commission of up to 3.0% of gross proceeds from each sale and be reimbursed for certain expenses incurred in connection with the agreement.

The offering is made pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on April 3, 2026, and a prospectus supplement filed on April 6, 2026.

Full analysis

The company has established a flexible capital raising mechanism through an at-the-market equity offering program, allowing it to opportunistically sell shares into the market over time rather than through a single, fixed-price offering. This structure provides Oncolytics with access to up to $75.0 million in equity capital while minimizing dilution risk since the company controls the timing and amount of sales. The intended use of proceeds focuses heavily on advancing the company's lead clinical asset, pelareorep, indicating continued investment in this development program alongside general corporate needs. The agreement includes standard terms for such arrangements, including a 3.0% commission to the sales agent and mutual termination rights with ten trading days' notice. The legal opinion filed as Exhibit 5.1 confirms the validity of the shares to be offered under this program.

ONCY · Oncolytics Biotech Inc.

Summary

Key takeaways

Full analysis